Last Update: Aug 6, 2023
Click to purchase the complete TPD database, including companies with pre-clinical programs (80+ rows) and additional notes.
| Company | Type | Candidate | MOA/Platform | Indications | Stage | Trial | Trial Initiation |
|---|---|---|---|---|---|---|---|
| Bristol Myers Squibb | Public | Iberdomide | IKZF1/3 molecular glue degrader | Multiple myeloma (MM) | III | NCT04975997 | July 2022 |
| Bristol Myers Squibb | Public | CC-92480 | IKZF1/3 molecular glue degrader | MM | III | NCT03989414 | Sep 2019 |
| Bristol Myers Squibb | Public | CC-99282 | IKZF1/3 molecular glue degrader | r/r NHL | II | NCT03930953 | May 2019 |
| Arvinas | Public | Bavdegalutamide | PROTAC targeting AR | mCRPC | II | NCT03888612 | March 2019 |
| Arvinas & Pfizer | Public | ARV-471 | PROTAC targeting ER | ER+ HER2- metastatic BC (+- Ibrance) | II | NCT04072952 | Aug 2019 |
| Arvinas | Public | ARV-766 | PROTAC targeting AR | mCRPC | II | NCT05067140 | Sep 2021 |
| Ranok Therapeutics | Private | RNK05047 | BRD4-targeting protein degrader (chaperone-mediated) | Advanced solid tumors or DLBCL | I/II | NCT05487170 | Aug 24 2022 |
| C4 Therapeutics | Public | CFT7455 | IKZF1/3 molecular glue degrader | r/r NHL or MM | I/II | NCT04756726 | June 2021 |
| Novartis | Public | DKY709 | IKZF2 molecular glue degrader | Advanced solid tumors (NSCLC, Melanoma, CRC, TNBC) | I/Ib | NCT03891953 | May 2019 |
| Kangpu Biopharmaceuticals | Private | KPG-818 | IKZF1/3 molecular glue degrader (lenalidomide analog) | SLE | IIa | NCT04643067 | June 2022 |
| Bristol Myers Squibb | Public | CC-90009 | GSPT1 molecular glue degrader | AML (combo therapy) | Ib | NCT04336982 | Aug 2020 |
| Bristol Myers Squibb | Public | CC-94676 | PROTAC targeting AR | mCRPC | I | NCT04428788 | Jun 2020 |
| Kymera Therapeutics & Sanofi | Public | KT-474 | PROTAC targeting IRAK4 | IL-1R/TLR-driven diseases (HS, AD) | I | NCT04772885 | Feb 2021 |
| Nurix Therapeutics | Public | NX-2127 | PROTAC targeting BTK + IKZF1/3 | CLL, SLL, WM, MCL, MZL, FL, DLBCL | I | NCT04830137 | May 2021 |
| Foghorn Therapeutics | Public | FHD-609 | PROTAC targeting BRD9 | Advanced synovial sarcoma, SMARCB1-deleted tumors | I | NCT04965753 | Aug 2021 |
| Dialectic Therapeutics | Private | DT2216 | PROTAC targeting BCL-XL | r/r Solid tumors + Hematological malignancies | I | NCT04886622 | Oct 2021 |
| Bristol Myers Squibb | Public | BMS-986397 | CK1α molecular glue degrader | r/r AML, MDS | I | NCT04951778 | Dec 2021 |
| Kangpu Biopharmaceuticals | Private | KPG-818 | IKZF1/3 molecular glue degrader | Hematological malignancies | I | NCT04283097 | May 2020 |
| Kangpu Biopharmaceuticals | Private | KPG-121 | CK1α molecular glue degrader | mCRPC | I | NCT03569280 | Nov 2019 |
| Haisco Pharmaceutical Group | Public | HSK29116 | PROTAC targeting BTK | r/r B cell malignancies | I | NCT04861779 | Aug 2021 |
| Kymera Therapeutics | Public | KT-413 | PROTAC targeting IRAK4 + IKZF1/3 | MYD88-mutant tumors | I | NCT05233033 | June 2022 |
| Kymera Therapeutics | Public | KT-333 | PROTAC targeting STAT3 | r/r NHL, PTCL, CTCL, LGL-L, Solid tumors | I | NCT05225584 | Jan 2022 |
| BioTheryX | Private | BTX-1188 | GSTP1 + IKZF1/3 molecular glue degrader | Hematological malignancies (NHL, AML), Solid tumors | I | NCT05144334 | Jan 2022 |
| C4 Therapeutics | Public | CFT8634 | PROTAC targeting BRD9 | Metastatic SMARCB1-perturbed cancers (synovial sarcoma, SMARCB1-null tumors) | I/II | NCT05355753 | March 2022 |
| Nurix Therapeutics | Public | NX-5948 | PROTAC targeting BTK | CLL, SLL, DLBCL, FL, MCL, MZL, WM, PCNSL | I | NCT05131022 | Apr 2022 |
| Hinova Pharmaceuticals | Private | HP518 | PROTAC targeting AR | mCRPC | I | NCT05252364 | Feb 2022 |
| Kintor Pharmaceutical | Public | GT20029 | PROTAC targeting AR (topical formulation) | Androgenic alopecia, Acne vulgaris | I | NCT05428449 | Feb 2022 |
| Astellas Pharma | Public | ASP3082 | PROTAC targeting KRAS G12D | Advanced/metastatic r/r solid tumors with KRAS G12D mutations | I | NCT05382559 | Jun 2022 |
| Orum Therapeutics | Private | ORM-5029 | GSPT1 molecular glue degrader-anti-HER2 mAb (pertuzumab) conjugate | HER2-expressing advanced solid tumors | I | NCT05511844 | Oct 2022 |
| Monte Rosa Therapeutics | Public | MRT-2359 | GSPT1 molecular glue degrader | Myc-driven NSCLC, SCLC, DLBCL, high-grade neuroendocrine cancer, solid tumors | I/II | NCT05546268 | Nov 2022 |
| C4 Therapeutics | Public | CFT1946 | PROTAC targeting BRAF V600X | BRAF V600X driven cancers (melanoma, CRC, NSCLC) | I/II | NCT05668585 | Dec 2022 |
| Accutar Biotech | Private | AC0682 | PROTAC targeting ERα | ER+ breast cancer | I | NCT05080842 | Nov 2021 |
| Accutar Biotech | Private | AC0176 | PROTAC targeting AR | Metastatic castration-resistant prostate cancer | I | NCT05241613 | Feb 2023 |
| Prelude Therapeutics | Public | PRT3789 | SMARCA2 degrader | SMARCA4-mutated NSCLC and other tumors | I | NCT05639751 | Feb 2023 |
| Accutar Biotech | Private | AC0676 | PROTAC targeting BTK | B cell malignancies | I | NCT05780034 | Q2-Q3 |
| Autotac Bio | Private | ATC-102 | AUTOTAC targeting Tau | Alzheimer's disease | I | - | - |
| Cullgen | Private | CG001419 | TRK degrader | NTRK fusion-positive cancers | IND cleared | - | - |